Sedation In ICU Setting Market Size, Share and Industry Analysis By Drug/Drug Class (Propofol, Benzodiazepams (Midazolam, etc.), Dexmedetomidine, Remifentanil), and Regional Forecast 2019-2032

Table of Content:

1. Introduction

    1.1. Research Scope

    1.2. Market Segmentation

    1.3. Research Methodology

    1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

    3.1. Market Drivers

    3.2. Market Restraints

    3.3. Market Opportunities

4. Key Insights

    4.1. Guidelines for Sedation in ICU Setting – forKey Countries

    4.2. Technological Advancements

    4.3. Pipeline Analysis

    4.4. Advantages & Disadvantages of VariousTypes of Sedation in ICU Setting by Drug Class.

5. Global Sedation in ICU Setting MarketAnalysis, Insights, and Forecast, 2015-2026

    5.1. Key Findings / Summary

    5.2. Market Analysis,Insights and Forecast – By Drug/Drug Class

        5.2.1. Propofol

        5.2.2. Benzodiazepams (Midazolam, etc.)

        5.2.3. Dexmedetomidine

        5.2.4. Remifentanil

        5.2.5. Others

    5.3. Market Analysis,Insights, and Forecast – By Region

        5.3.1. North America

        5.3.2. Europe

        5.3.3. Asia Pacific

        5.3.4. Rest of World

6. North America Sedation in ICU Setting MarketAnalysis, Insights, and Forecast, 2015-2026

    6.1. Key Findings /Summary

    6.2. Market Analysis,Insights, and Forecast – By Drug/Drug Class

        6.2.1. Propofol

        6.2.2. Benzodiazepams (Midazolam, etc.)

        6.2.3. Dexmedetomidine

        6.2.4. Remifentanil

        6.2.5. Others

    6.3. Market Analysis,Insights, and Forecast – By Country

        6.3.1. U.S.

        6.3.2. Canada

7. Europe Sedation in ICU Setting MarketAnalysis, Insights, and Forecast, 2015-2026

    7.1. Key Findings /Summary

    7.2. Market Analysis,Insights, and Forecast – By Drug/Drug Class

        7.2.1. Propofol

        7.2.2. Benzodiazepams (Midazolam, etc.)

        7.2.3. Dexmedetomidine

        7.2.4. Remifentanil

        7.2.5. Others

    7.3. Market Analysis,Insights, and Forecast – By Country/Sub-region

        7.3.1. U.K.

        7.3.2. Germany

        7.3.3. France

        7.3.4. Italy

        7.3.5. Spain

        7.3.6. Sweden

        7.3.7. Norway

        7.3.8. Denmark

        7.3.9. Finland

        7.3.10.Benelux

        7.3.11.Russia

        7.3.12.Rest of Europe

8. Asia Pacific Sedation in ICU Setting MarketAnalysis, Insights and Forecast, 2015-2026

    8.1. Key Findings /Summary

    8.2. Market Analysis,Insights, and Forecast – By Drug/Drug Class

        8.2.1. Propofol

        8.2.2. Benzodiazepams (Midazolam, etc.)

        8.2.3. Dexmedetomidine

        8.2.4. Remifentanil

        8.2.5. Others

    8.3. Market Analysis,Insights, and Forecast – By Country/Sub-region

        8.3.1. Japan

        8.3.2. China

        8.3.3. India

        8.3.4. South Korea

        8.3.5. Rest of Asia Pacific

9. Rest of World Sedation in ICU Setting MarketAnalysis, Insights and Forecast, 2015-2026

    9.1. Key Findings /Summary

    9.2. Market Analysis,Insights, and Forecast – By Drug/Drug Class

        9.2.1. Propofol

        9.2.2. Benzodiazepams (Midazolam, etc.)

        9.2.3. Dexmedetomidine

        9.2.4. Remifentanil

        9.2.5. Others

10.Competitive Analysis

    10.1 KeyIndustry Developments

    10.2 GlobalMarket Share Analysis (2018)

    10.3 Competition Dashboard

    10.4 Comparative Analysis – Major Players

    10.5 CompanyProfiles (Overview, Products & services, SWOT analysis, Recentdevelopments, strategies, financials     (based on availability))

        10.5.1.Astra Zeneca

        10.5.2.GlaxoSmithKline

        10.5.3.Mylan N.V.

        10.5.4.Fresenius Kabi

        10.5.5.Teva Pharmaceutical Industries

        10.5.6.B. Braun Medical

        10.5.7.Aspen Holdings

        10.5.8.Other prominent players

11. Strategic Recommendations